general
- Generic Name : Ziprasidone
- Pronunciation : zi-PRAS-i-done
- ICD Code : Y49.5
- Therapeutic Classification : Antipsychotics
- Trade Names/Brand Names of Ziprasidone(India) :
Zipsydon (40 mg),Zipsydon (80 mg),Azona,Zipsydon (60 mg),Azona (40 mg),Azona (80 mg),Zipsydon - International :
Geodon
prescription
This medication, an antipsychotic agent, is prescribed for schizophrenia, a mental illness characterized by disturbed thinking, apathy, and strong emotions. It regulates specific brain chemical activities that influence thinking and behavior.
risk factors
- Not recommended for patients with a history of heart diseases, elderly individuals with dementia, or those with a known hypersensitivity to this drug.
- Regularly monitor blood sugar levels in diabetic patients or those at risk of developing diabetes.
- Monitor complete blood count regularly in patients with pre-existing blood disorders.
side effects
- Most Common: Nausea, vomiting, drowsiness, runny nose, weakness
- Central Nervous System: Headache, lethargy, muscle stiffness, movement disorder, tremor, paralysis, and twitching
- Heart: Tachycardia, hypertension, and postural hypotension
- Gastrointestinal: Anorexia, dysphagia, indigestion, and rectal bleeding
- Hormonal: Hyperprolactinemia
- Genitourinary: Amenorrhea, impotence, and gynecomastia
- Metabolic: Weight gain
- Skin: Rash
- Respiratory: Respiratory tract infection and cough
- Potentially Fatal: Hematologic and neurological disorders
dosage
For adults with schizophrenia:
Oral administration:
– Hydrochloride (HCl) formulation:
– Initial dose: 20 mg twice daily, gradually increased to 80 mg twice daily if necessary.
– Maintenance dose: 20 mg twice daily.
how to take
It is available as a capsule for oral administration, typically taken twice daily with food.
warning
- Use caution in patients with a history of Alzheimer’s disease, coronary artery disease, irregular heartbeat, low blood pressure, severe dizziness or fainting, diabetes, stroke, seizures, Neuroleptic malignant syndrome, obesity, swallowing difficulties, pneumonia, low white blood cell count, liver or kidney impairment, and during pregnancy and breastfeeding
- Discontinue medication if an increased risk of QT prolongation occurs
- Avoid driving or operating machinery due to potential drowsiness or dizziness
- Monitor ECG in patients displaying symptoms of torsades de pointes (e.g., syncope, dizziness, palpitations)
- Monitor serum electrolyte levels in patients receiving concurrent diuretic therapy
storage
Injection: Store between 15-30°C. Protect from light by storing in an airtight container. Keep out of reach of children.